Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Liver transplantation and hepatitis C.

M Willems1, H J Metselaar, H W Tilanus

  • 1Department of Gastroenterology, University Hospital Dijkzigt, P.O. Box 2040, 3000 Rotterdam, The Netherlands. devlaming@mdl.azr.nl

Transplant International : Official Journal of the European Society for Organ Transplantation
|April 6, 2002
PubMed
Summary

Hepatitis C virus (HCV) recurrence after liver transplant can cause rapid liver damage. Early antiviral combination therapy may prevent severe complications and cirrhosis, improving long-term outcomes for transplant recipients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tremors and Health-Related Quality of Life in Liver Transplant Recipients: Post-hoc Analysis of a Multicenter, Randomized, Controlled Trial Comparing a Life Cycle Pharma-Tacrolimus Regimen and Extended-Release Tacrolimus Regimen.

Transplant international : official journal of the European Society for Organ Transplantation·2025
Same author

De Novo Balanced Translocations Disrupting the FBN1 Gene Diagnosed by Genome Sequencing: An Uncommon Cause of Marfan Syndrome Modifying Genetic Counseling.

American journal of medical genetics. Part A·2024
Same author

Exploring the genetic causes of isolated short stature. What has happened to idiopathic short stature?

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2023
Same author

Adherence to guideline recommendations for Barrett's esophagus (BE) surveillance endoscopies: Effects of dedicated BE endoscopy lists.

Endoscopy international open·2023
Same author

Identification of the first homozygous intragenic deletion in the YY1AP1 gene in a consanguineous family: New insights into the phenotypic variability associated with Grange syndrome.

American journal of medical genetics. Part A·2023
Same author

Should we perform oocyte accumulation to preserve fertility in women with Turner syndrome? A multicenter study and systematic review of the literature.

Human reproduction (Oxford, England)·2023

Area of Science:

  • Hepatology
  • Transplantation Immunology
  • Virology

Background:

  • Chronic hepatitis C virus (HCV) infection is a primary cause of end-stage liver disease and a common indication for liver transplantation.
  • Post-transplant HCV recurrence is frequent, with rapid progression to severe liver damage, including fibrosis and cirrhosis, often exacerbated by immunosuppression.
  • Some patients experience cholestatic liver disease and chronic rejection, potentially requiring retransplantation.

Purpose of the Study:

  • To evaluate the impact of post-liver transplant hepatitis C virus recurrence on graft and patient outcomes.
  • To assess the efficacy of early antiviral combination therapy (interferon and ribavirin) in preventing disease progression and complications.
  • To explore optimal antiviral strategies for patients with decompensated cirrhosis awaiting or undergoing transplantation.

Related Experiment Videos

Main Methods:

  • Review of clinical outcomes and histological findings in liver transplant recipients with recurrent hepatitis C.
  • Analysis of viral replication markers in the early post-transplant period.
  • Evaluation of the effectiveness of combination antiviral therapy initiated shortly after transplantation.

Main Results:

  • HCV replication is detectable within days post-transplantation, leading to progressive liver damage.
  • While short-term survival rates are satisfactory, severe complications from recurrent HCV disease are expected within 10-20 years.
  • The potential benefit of early interferon and ribavirin combination therapy in preventing rapid cirrhosis and chronic rejection requires further investigation through larger studies.

Conclusions:

  • Liver transplantation remains a viable option for end-stage liver disease due to chronic hepatitis C.
  • Early intervention with antiviral therapy post-transplantation is crucial to mitigate the morbidity and mortality associated with HCV recurrence.
  • Future research should focus on randomized trials to confirm the efficacy of combination therapy and explore pre-transplant antiviral strategies.